As of August 04, 2026, OnKure Therapeutics's top three insider holders are Braden Michael Leonard (TenPercentOwner, 3.46Mn shares), Holdings A/S Novo (TenPercentOwner, 3.33Mn shares), Bioventures, L.P. Acorn (TenPercentOwner, 2.84Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Edward T Mathers | - | 15,310 | 0 | 02 Jan, 2026 |
| Braden Michael Leonard | - | 0 | 3,457,395 | 26 Sep, 2024 |
| Holdings A/S Novo | - | 3,330,337 | 0 | 23 Jun, 2023 |
| Asset Management, Lp Cormorant | - | 0 | 1,813,439 | 14 May, 2025 |
| Alejandro Dorenbaum | Chief Medical Officer | 30,000 | 0 | 13 Dec, 2022 |
| Nicholas A Saccomano | President And Ceo | 7,333 | 0 | 24 Mar, 2026 |
| Isaac Manke | - | 20,583 | 0 | 02 Jan, 2026 |
| R Michael Carruthers | - | 4,939 | 0 | 08 Oct, 2024 |
| Jason A. Leverone | Chief Financial Officer | 16,000 | 0 | 24 Mar, 2026 |
| Gregory J. Flesher | President And Ceo | 109,600 | 0 | 13 Dec, 2021 |
| Bioventures, L.P. Acorn | - | 1,709,944 | 1,129,730 | 19 May, 2025 |
| Niall O'Donnell | - | 0 | 2,188,713 | 10 May, 2023 |
| Bali Muralidhar | - | 0 | 2,073,957 | 14 Jul, 2021 |
| Ashley Hall | Chief Development Officer | 39,600 | 0 | 29 Aug, 2023 |
| Michael Cruse | Chief Operating Officer | 31,758 | 0 | 31 Aug, 2022 |
| Vineet R. Jindal | Chief Financial Officer | 36,600 | 0 | 13 Dec, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Nicholas A Saccomano | Employee Stock Option (right to buy) | A | 330,000 | $0.00 | 330,000 | D | A |
| 01 Apr, 2026 | Nicholas A Saccomano | Employee Stock Option (right to buy) | A | 330,000 | $0.00 | 330,000 | D | A |
| 01 Apr, 2026 | Nicholas A Saccomano | Employee Stock Option (right to buy) | A | 330,000 | $0.00 | 330,000 | D | A |
| 01 Apr, 2026 | Jason A. Leverone | Employee Stock Option (right to buy) | A | 110,000 | $0.00 | 110,000 | D | A |
| 01 Apr, 2026 | Dylan Hartley | Employee Stock Option (right to buy) | A | 110,000 | $0.00 | 110,000 | D | A |
| 01 Apr, 2026 | Samuel Agresta | Employee Stock Option (right to buy) | A | 110,000 | $0.00 | 110,000 | D | A |
| 23 Mar, 2026 | Jason A. Leverone | Class A Common Stock | D | 301 | $4.16 | 16,000 | D | S |
| 23 Mar, 2026 | Nicholas A Saccomano | Class A Common Stock | D | 86 | $4.16 | 7,333 | D | S |
| 23 Mar, 2026 | Nicholas A Saccomano | Class A Common Stock | D | 86 | $4.16 | 7,333 | D | S |
| 23 Mar, 2026 | Nicholas A Saccomano | Class A Common Stock | D | 86 | $4.16 | 7,333 | D | S |
| 31 Dec, 2025 | Isaac Manke | Class A Common Stock | A | 5,258 | $0.00 | 20,583 | D | A |
| 31 Dec, 2025 | Edward T Mathers | Class A Common Stock | A | 3,911 | $0.00 | 15,310 | D | A |
| 22 Dec, 2025 | Nicholas A Saccomano | Class A Common Stock | D | 87 | $2.97 | 7,419 | D | S |
| 22 Dec, 2025 | Nicholas A Saccomano | Class A Common Stock | D | 87 | $2.97 | 7,419 | D | S |
| 22 Dec, 2025 | Nicholas A Saccomano | Class A Common Stock | D | 87 | $2.97 | 7,419 | D | S |
| 22 Dec, 2025 | Jason A. Leverone | Class A Common Stock | D | 302 | $2.97 | 16,301 | D | S |
| 30 Sep, 2025 | Edward T Mathers | Class A Common Stock | A | 4,125 | $0.00 | 11,399 | D | A |
| 30 Sep, 2025 | Isaac Manke | Class A Common Stock | A | 5,545 | $0.00 | 15,325 | D | A |
| 22 Sep, 2025 | Nicholas A Saccomano | Class A Common Stock | D | 88 | $2.62 | 3,506 | D | S |
| 22 Sep, 2025 | Nicholas A Saccomano | Class A Common Stock | D | 88 | $2.62 | 3,506 | D | S |